Kazia Therapeutics


AU$23m market cap

AU$0.32 last close

Kazia Therapeutics has two clinical stage anti-cancer drugs: GDC-0084 (targeting glioblastoma) and Cantrixil (targeting ovarian cancer). GDC-0084 was inlicensed from Genentech, and Kazia is seeking other in-licence opportunities.

Investment summary

Kazia Therapeutics’ FY19 financial results show cash of A$5.4m and an operational cash use of A$6.7m. The 20-patient efficacy cohort in the lead GDC-0084 Phase IIa study should report data in Q419. Kazia has announced a new trial collaborating with the prestigious MSK hospital in NY to look at GDC-0084 in PI3K mutated brain metastases in conjunction with radiotherapy. Initial efficacy data from the Cantrixil ovarian cancer Phase I is also due in Q419. Our base-case value, updated for year-end cash, is A$137m.

Y/E Jun
Revenue (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 2.9 (10.9) (11.0) (22.2) N/A N/A
2019A 1.5 (7.6) (7.7) (12.9) N/A N/A
2020E 1.5 (8.7) (8.7) (14.0) N/A N/A
2021E 1.5 (11.1) (11.1) (17.9) N/A N/A
Last updated on 20/06/2019
Industry outlook

Kazia Therapeutics is listed on the ASX and NASDAQ. Its two drug technology platforms are GDC-0084, a PI3K inhibitor licensed from Genentech, and a Cantrixil, a third-generation benzopyrans.

Last updated on 20/06/2019
Share price graph
Balance sheet
Forecast net debt (A$m) 8.3
Forecast gearing ratio (%) 184
Key management
Iain Ross Chairman
James Garner CEO

Content on Kazia Therapeutics